SunTrust Robinson Humphrey Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
August 5, 2016 10:00 AM EDTBMO Capital analyst Alex Arfaei weighed in on Bristol-Myers Squibb Co. (NYSE: BMY) after the company announced that announced that in CheckMate-026 (CM-026), a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Opdivo did not meet the trial's primary endpoint of progression-free survival (PFS) in patients expressing PD-L1 >= 5%. Arfaei calls this a significantly negative for BMY and positive for Merck (NYSE:... More
Bristol-Myers Squibb (BMY) Says CheckMate -026 Trial for Opdivo Missed Primary Endpoint
August 5, 2016 8:21 AM EDTBristol-Myers Squibb Company (NYSE: BMY) announced that CheckMate -026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at 5%. The company will complete a full evaluation of the... More
